Published in Osteoporos Int on July 02, 2009
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int (2015) 1.46
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int (2010) 0.99
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int (2011) 0.96
Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol (2010) 0.93
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Using multiple types of studies in systematic reviews of health care interventions--a systematic review. PLoS One (2013) 0.81
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging (2011) 0.79
Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int (2013) 0.78
Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol (2015) 0.75
Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical Studies. J Burn Care Res (2016) 0.75
Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open (2013) 0.75
Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG. Rheumatol Int (2010) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas (2004) 2.03
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med (1999) 2.01
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Empirical comparisons of proportional hazards and logistic regression models. Stat Med (1989) 1.87
Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res (2008) 1.78
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int (2006) 1.61
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone (1993) 1.53
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res (2007) 1.45
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab (1997) 1.25
Study subjects and ordinary patients. Osteoporos Int (2000) 1.19
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res (2004) 1.14
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.12
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab (2000) 1.10
Consequences of poor compliance with bisphosphonates. Bone (2007) 1.09
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin (2007) 1.08
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin (2006) 1.08
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int (2004) 1.07
Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int (2007) 0.99
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin (2004) 0.95
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol (2008) 0.90
A new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. Int J Technol Assess Health Care (1993) 0.87
Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int (2001) 0.76
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med (2001) 4.96
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis. Haemophilia (2003) 2.72
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg (2001) 1.74
Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia (2012) 1.55
Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys (1998) 1.50
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 1.36
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A (1995) 1.32
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int (2012) 1.29
Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. Osteoporos Int (2011) 1.28
Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost (2011) 1.17
Matrix-bound protein subunits. Biochem Biophys Res Commun (1970) 1.15
Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology (1999) 1.14
Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia (2004) 1.14
High-level expression and mutagenesis of recombinant human phosphatidylcholine transfer protein using a synthetic gene: evidence for a C-terminal membrane binding domain. Biochemistry (2000) 1.12
Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int (2006) 1.12
Safety of human albumin--serious adverse events reported worldwide in 1998-2000. Br J Anaesth (2003) 1.11
Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures. Osteoporos Int (2011) 1.11
The aetiology of heart failure in the Chinese population of Hong Kong--a prospective study of 730 consecutive patients. Int J Cardiol (1995) 1.07
Studies on protein subunits. II. Preparation and properties of active subunits of aldolase bound to a matrix. Arch Biochem Biophys (1972) 1.05
A nonpeptidyl growth hormone secretagogue. Science (1993) 1.04
Central venous access devices in haemophilia. Haemophilia (2004) 1.02
Albumin administration--what is the evidence of clinical benefit? A systematic review of randomized controlled trials. Eur J Anaesthesiol (2003) 1.01
Studies on protein subunits. 3. Kinetic evidence for the presence of active subunits during the renaturation of muscle aldolase. J Biol Chem (1973) 1.00
Separation and properties of isozymes of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthetase from Saccharomyces cerevisiae. Can J Biochem (1971) 1.00
The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology (1989) 0.97
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int (2014) 0.94
Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. J Thromb Haemost (2011) 0.93
Active subunits of transaldolase bound to sepharose. Eur J Biochem (1973) 0.93
A novel 3-substituted benzazepinone growth hormone secretagogue (L-692,429). J Med Chem (1994) 0.93
Aconitine poisoning due to Chinese herbal medicines: a review. Vet Hum Toxicol (1994) 0.93
A complex between the catalytic and regulatory subunits of aspartate transcarbamylase. J Biol Chem (1973) 0.92
Improved precision with Hologic Apex software. Osteoporos Int (2008) 0.91
The effect of transcutaneous electrical nerve stimulation on coronary and systemic haemodynamics in syndrome X. Coron Artery Dis (1996) 0.91
Inhibition of leucine aminopeptidase by amino acid hydroxamates. J Biol Chem (1982) 0.89
Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J (1995) 0.89
Requirement of lysine residues outside of the proposed pentasaccharide binding region for high affinity heparin binding and activation of human antithrombin III. J Biol Chem (1996) 0.89
Pruritus. A manifestation of iron deficiency. JAMA (1976) 0.87
Effects of subunit interactions on the activity of lactate dehydrogenase studied in immobilized enzyme systems. Biochemistry (1976) 0.87
Erratum to: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int (2015) 0.87
Subunit interactions in aspartate transcarbamylase. A model for the allosteric mechanism. J Biol Chem (1975) 0.86
Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-D-Phe-Lys-NH2-induced growth hormone release from rat primary pituitary cells. Endocrinology (1991) 0.86
Multiple sites and synergism in the binding of inhibitors to microsomal aminopeptidase. Biochemistry (1988) 0.85
Purification and properties of phosphoprotein phosphatases with different substrate and divalent cation specificities from canine heart. Eur J Biochem (1978) 0.85
Some experimental approaches for studying subunit interactions in enzymes. Can J Biochem (1976) 0.85
Synergistic binding of inhibitors to the protease from HIV type 1. Biochem J (1996) 0.84
Analysis of the interactions between an enzyme and multiple inhibitors using combination plots. Biochem J (1996) 0.84
A method for the complete S sulfonation of cysteine residues in proteins. Biochemistry (1968) 0.83
On the mechanism of assembly of the aspartate transcarbamoylase from Escherichia coli. Eur J Biochem (1978) 0.83
Co-purification of type I alkaline phosphatase and type I phosphoprotein phosphatase from various animal tissues. Arch Biochem Biophys (1981) 0.83
Affinity chromatography of a regulatory enzyme based on specific interaction with the effector. Biochem Biophys Res Commun (1969) 0.83
Subunit interactions in aspartate transcarbamylase. Characterization of a complex between the catalytic and the regulatory subunits. J Biol Chem (1975) 0.82
Immobilized subunits. Methods Enzymol (1976) 0.82
Ligand interactions at the active site of aspartate transcarbamoylase from Escherichia coli. Biochemistry (1986) 0.82
Synergistic binding of hydrophobic probes and zinc ligands to thermolysin. Eur J Biochem (1993) 0.82
Primary plague septicemia. Case report. Rocky Mt Med J (1978) 0.82
Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology (1993) 0.81
Phosphorus-containing inhibitors of aspartate transcarbamoylase from Escherichia coli. FEBS Lett (1990) 0.81
Structure and function of aspartate transcarbamoylase studied using chymotrypsin as a probe. Can J Biochem (1978) 0.81
Synergistic binding of ligands to angiotensin-converting enzyme. J Biol Chem (1988) 0.81
Studies on protein subunits. V. Specific interaction between matrix-bound subunits of aldolase and soluble aldolase subunits. Can J Biochem (1973) 0.80
Stabilization of the relaxed state of aspartate transcarbamoylase by modification with a bifunctional reagent. J Biol Chem (1978) 0.80
Oral treatment of peritonitis in CAPD patients with ofloxacin. Nephrol Dial Transplant (1988) 0.80
Inhibition of L-692,429-stimulated rat growth hormone release by a weak substance P antagonist: L-756,867. J Endocrinol (1997) 0.80
Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin. J Antimicrob Chemother (1988) 0.79
Improved prognosis since 1969 of myocardial infarction treated in a coronary care unit: lack of relation with changes in severity. BMJ (1989) 0.79
Continuous spectrophotometric assay of a sepharose-bound enzyme and its use to study kinetics of coupling of the enzyme to sepharose. Anal Biochem (1973) 0.79
Subunit interactions in aspartate trancarbamylase from Escherichia coli studied using matrix-bound derivatives. FEBS Lett (1974) 0.78
Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporos Int (2011) 0.78
Further studies on aspartate transcarbamoylase: molecular weight of the c3r6 complex and analysis of succinate inhibition in the native enzyme. Can J Biochem (1976) 0.78
Effects of gonadal hormones on calcium-binding protein in chick duodenum. Am J Physiol (1979) 0.78
Conformation of cross-linked aspartate transcarbamoylase. Can J Biochem (1981) 0.78
Vertebroplasty and kyphoplasty in 2001. J Clin Densitom (2001) 0.78
L-leucinthiol - a potent inhibitor of leucine aminopeptidase. Biochem Biophys Res Commun (1983) 0.78
A novel non-peptidyl growth hormone secretagogue. Horm Res (1993) 0.77
Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. Eur J Pharmacol (1994) 0.77
Topography of preemptying ventricular segments in patients with Wolff-Parkinson-White syndrome using scintigraphic phase mapping and esophageal pacing. Circulation (1983) 0.77
Subunit interactions in aspartate transcarbamylase. The interaction between catalytic and regulatory subunits and the effect of ligands. J Biol Chem (1975) 0.77
Increase in testis luteinizing hormone receptor by estrogen in mice susceptible to Leydig cell tumors. Cancer Res (1981) 0.76
Effects of electroacupuncture and gonadotropin-releasing hormone treatments on hormonal changes in anoestrous sows. Am J Chin Med (1988) 0.76
Electrical off response of cat esophageal smooth muscle: an analog simulation. Am J Physiol (1976) 0.76
Acyclic structural variants of growth hormone secretagogue L-692,429. Bioorg Med Chem Lett (1999) 0.76
Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone secretion from rat anterior pituitary cells. Biochem Biophys Res Commun (1999) 0.76
Functional changes in cocultures of mesencephalon and striatal neurons from embryonic C57/BL6 mice due to low concentrations of 1-methyl-4-phenylpyridinium (MPP+). J Neural Transm Gen Sect (1993) 0.76
Conformations of bound nucleoside triphosphate effectors in aspartate transcarbamylase. Evidence for the London-Schmidt model by transferred nuclear Overhauser effects. Biochemistry (1985) 0.76
Conformational states of aspartate transcarbamoylase stabilized with a cross-linking reagent. J Biol Chem (1979) 0.76
Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding. Haemophilia (2004) 0.76
Characteristics of fetal heart rate changes during the expulsive stage of bovine parturition in relation to fetal outcome. Am J Vet Res (1996) 0.76
Modulation of prolactin receptors in cultured rat granulosa cells by FSH, LH and GnRH. Mol Cell Endocrinol (1982) 0.76
Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures. J Neural Transm Suppl (1995) 0.75
Transoesophageal echocardiography. Postgrad Med J (1997) 0.75
Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII. Haemophilia (2004) 0.75
PMA-sensitive protein kinase C is not necessary in TRH-stimulated prolactin release from female rat primary pituitary cells. Life Sci (1992) 0.75
A case of acute aconitine poisoning caused by chuanwu and caowu. J Trop Med Hyg (1993) 0.75
Hybrid aspartate transcarbamoylase containing cross-linked subunits. Can J Biochem (1981) 0.75